Interferon beta-1b vs peginterferon beta-1a

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanisms: Interferon beta receptor (type I IFN signaling) · Type I interferon receptor · full Multiple Sclerosis pipeline

Interferon beta-1b

Marketed by Bayer

Approved in Multiple Sclerosisbiologic (interferon)
Partial signal

NCT00099502 · Phase 3 · completed

The study was a large randomized, triple-blind, active-controlled trial comparing two interferon beta-1b doses with Copaxone, with relapse hazard as the clinical primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment); Time to Confirmed Expanded Disability Status Scale (EDSS) Progression Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With Confirmed EDSS Progression at Selected Points in Time (up to 60 months after start of treatment); Functional Assessment of Multiple Sclerosis (FAMS) Trial Outcome Index (TOI) at Month 60 (60 months after start of treatment): Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS (mixed)

Result source: NCT00185211

peginterferon beta-1a · Plegridy

Marketed by Biogen

Approved in Multiple Sclerosisbiologic
Reliable signal

NCT00906399 · Phase 3 · completed

This was a large, randomized, triple-blind, placebo-controlled trial with 1,516 participants. Its primary clinical endpoint, annualized relapse rate at one year, was statistically significantly lower with both peginterferon beta-1a schedules than with placebo (p=0.0007 for every 2 weeks and p=0.0114 for every 4 weeks).

Next expected readout: May 2027 · NCT03958877 (registry estimate)

Reported efficacy

Annualized Relapse Rate (ARR) at 1 Year: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481) (met)

Result source: NCT00906399

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInterferon beta-1bpeginterferon beta-1a
Annualised relapse rate0.2 vs 0.3−0.1 vs placebon 292NCT001852110.3 vs 0.4−0.1 vs placeboevery 4 weeks · wk 52 · n 500NCT00906399
2 other results
  • 0.3 vs 0.4 every 2 weeks · wk 52 · n 512 · Phase 3 · primary NCT00906399
  • 0 vs 0.5 125 µg · wk 96 · n 6 · Phase 3 · secondary NCT03870763
Free of 3-month confirmed disability progression (%)—Not posted · NCT00099502—Trial running · NCT03958877
New or enlarging T2 lesions—Not posted · NCT000995027.9 vs 10.9−3 vs placeboevery 4 weeks · wk 52 · n 462NCT00906399
1 other result
  • 3.6 vs 10.9 every 2 weeks · wk 52 · n 457 · Phase 3 · secondary NCT00906399

Annualised relapse rate

Interferon beta-1b
0.2 vs 0.3−0.1 vs placebon 292NCT00185211
peginterferon beta-1a
0.3 vs 0.4−0.1 vs placeboevery 4 weeks · wk 52 · n 500NCT00906399
2 other results
  • 0.3 vs 0.4 every 2 weeks · wk 52 · n 512 · Phase 3 · primary NCT00906399
  • 0 vs 0.5 125 µg · wk 96 · n 6 · Phase 3 · secondary NCT03870763

Free of 3-month confirmed disability progression (%)

Interferon beta-1b
—Not posted · NCT00099502
peginterferon beta-1a
—Trial running · NCT03958877

New or enlarging T2 lesions

Interferon beta-1b
—Not posted · NCT00099502
peginterferon beta-1a
7.9 vs 10.9−3 vs placeboevery 4 weeks · wk 52 · n 462NCT00906399
1 other result
  • 3.6 vs 10.9 every 2 weeks · wk 52 · n 457 · Phase 3 · secondary NCT00906399
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Interferon beta-1b: 6 of 6 rows · peginterferon beta-1a: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInterferon beta-1b
Rows use multiple source trials
peginterferon beta-1a
Rows use multiple source trials
Annualized Relapse
event rate · per year
No placebo or comparator arm
0.38 per year @ 24wka,b,c
NCT00370071 · Phase 3 · registry result, not featured evidence
0.142 per yearQ2Wd,a,b,c
NCT01332019 · Phase 3 · monotherapy
show 1 more dose
0.189 per yearQ4W
NCT01332019 · Phase 3 · monotherapy
New Active Lesion
event count · lesions
No placebo or comparator arm
-1.5 lesions @ 24wka,b,e
NCT00370071 · Phase 3 · registry result, not featured evidence
3.9 lesions @ 96wkQ2Wd,a,b,e
NCT01332019 · Phase 3 · monotherapy
show 1 more dose
9 lesions @ 96wkQ4W
NCT01332019 · Phase 3 · monotherapy
Dropout rate
7.2%f
NCT00185211 · Phase 3 · monotherapy
show 1 more result
5.1%
NCT00370071 · Phase 3 · registry result, not featured evidence
14.8%every 2 weeksg
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 9 more results
12.6%every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—every 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
50%125 µg
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
18.4%BIIB017 Plus Current FLS Therapy
NCT01939002 · Phase 3 · combination
18.4%BIIB017 Plus Naproxen
NCT01939002 · Phase 3 · combination
22.3%Q2W
NCT01332019 · Phase 3 · monotherapy
21.3%Q4W
NCT01332019 · Phase 3 · monotherapy
14%125 μg
NCT02587065 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
3.1%f
NCT00185211 · Phase 3 · monotherapy
show 1 more result
—
NCT00370071 · Phase 3 · registry result, not featured evidence
4.7%every 2 weeksg
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 9 more results
4.4%every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—every 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—125 µg
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
12.6%BIIB017 Plus Current FLS Therapy
NCT01939002 · Phase 3 · combination
13.3%BIIB017 Plus Naproxen
NCT01939002 · Phase 3 · combination
4%Q2W
NCT01332019 · Phase 3 · monotherapy
2.5%Q4W
NCT01332019 · Phase 3 · monotherapy
7.3%125 μg
NCT02587065 · Phase 4 · registry result, not featured evidence
Serious AEs
20.9%f
NCT00185211 · Phase 3 · monotherapy
show 1 more result
0%
NCT00370071 · Phase 3 · registry result, not featured evidence
10.7%every 2 weeksg
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 9 more results
14%every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
8.9%every 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
15.3%every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0%125 µg
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
3.9%BIIB017 Plus Current FLS Therapy
NCT01939002 · Phase 3 · combination
6.1%BIIB017 Plus Naproxen
NCT01939002 · Phase 3 · combination
16.6%Q2W
NCT01332019 · Phase 3 · monotherapy
21.6%Q4W
NCT01332019 · Phase 3 · monotherapy
0%125 μg
NCT02587065 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
f
injection site reaction 55.8% (placebo 40.3%)
flu syndrome 52.1% (placebo 51.1%)
multiple sclerosis 38.4% (placebo 46.6%)
NCT00185211 · Phase 3 · monotherapy
show 1 more result
influenza like illness 41%
hepathic function abnormal 17.9%
headache 15.4%
NCT00370071 · Phase 3 · registry result, not featured evidence
every 2 weeksg
injection site erythema 61.4% (placebo 6.6%)
influenza like illness 46.4% (placebo 12.6%)
pyrexia 44.2% (placebo 15%)
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 9 more results
every 4 weeks
injection site erythema 56.4% (placebo 6.6%)
influenza like illness 46.8% (placebo 12.6%)
pyrexia 43.6% (placebo 15%)
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
every 2 weeks
injection site erythema 48.4% (placebo 6.6%)
influenza like illness 43.8% (placebo 12.6%)
pyrexia 31.1% (placebo 15%)
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
every 4 weeks
injection site erythema 48.1% (placebo 6.6%)
influenza like illness 45.3% (placebo 12.6%)
pyrexia 31.4% (placebo 15%)
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
125 µg
headache 66.7% (placebo 33.3%)
abdominal pain 33.3% (placebo 0%)
anxiety 16.7% (placebo 0%)
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
injection site erythema 44.7%
injection site reaction 22.3%
injection site pruritus 11.7%
NCT01939002 · Phase 3 · combination
injection site erythema 34.7%
injection site reaction 21.4%
influenza like illness 13.3%
NCT01939002 · Phase 3 · combination
Q2W
influenza like illness 42.8%
injection site erythema 41%
headache 29.4%
NCT01332019 · Phase 3 · monotherapy
Q4W
influenza like illness 44.2%
injection site erythema 42%
multiple sclerosis relapse 29.3%
NCT01332019 · Phase 3 · monotherapy
125 μg
influenza like illness 14.5%
injection site reactions 5.2%
pyrexia 5.2%
NCT02587065 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eAssessment timepoints differ: 96 weeks versus 24 weeks.
  6. fPopulation comparability has not been reviewed for these studies.
  7. gPopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Interferon beta-1b

Time to CDMS 26.9% (n=292) vs 45% (n=176) placebo @ 104wk
absolute value · percentage points
NCT00185211 · Phase 3 · monotherapy
show 2 more results
36.7% (n=292) vs 51.2% (n=176) placebo @ 156wk
NCT00185211 · Phase 3 · monotherapy
46.2% (n=292) vs 57.3% (n=176) placebo @ 260wk
NCT00185211 · Phase 3 · monotherapy
Time to EDSS Progression 12.8% (n=292) vs 19.9% (n=176) placebo @ 104wk
absolute value · percentage points
NCT00185211 · Phase 3 · monotherapy
show 2 more results
16.8% (n=292) vs 25.3% (n=176) placebo @ 156wk
NCT00185211 · Phase 3 · monotherapy
24.9% (n=292) vs 28.9% (n=176) placebo @ 260wk
NCT00185211 · Phase 3 · monotherapy
FAMS TOI 125 vs 125 placebo score @ 260wk
absolute value · score
NCT00185211 · Phase 3 · monotherapy
Time to MS McDonald 9.4 vs 6 placebo months
time to event · months
NCT00185211 · Phase 3 · monotherapy
MSFC Z 0.226 vs 0.225 placebo score @ 260wk
absolute value · score
NCT00185211 · Phase 3 · monotherapy
Newly Active Lesions 4 vs 7 placebo count @ 260wk
event count · count
NCT00185211 · Phase 3 · monotherapy
T2 Lesion Volume -123 vs -194.5 placebo mm @ 260wk
absolute change · mm
NCT00185211 · Phase 3 · monotherapy
Black Hole Volume 0 vs 0 placebo mm @ 260wk
absolute change · mm
NCT00185211 · Phase 3 · monotherapy
Brain Volume -2.281% (n=141) vs -1.771% (n=80) placebo @ 260wk
percent change · % of baseline
NCT00185211 · Phase 3 · monotherapy
New Gd-Enhancing Lesions -0.5 lesions @ 24wk
event count · lesions
No placebo or comparator arm
NCT00370071 · Phase 3 · registry result, not featured evidence
New or Enlarged T2 Lesion Count 0 lesions @ 24wk
absolute change · lesions
No placebo or comparator arm
NCT00370071 · Phase 3 · registry result, not featured evidence
Gd-enhancing Lesion Volume 93 mm @ 12wk
absolute value · mm
No placebo or comparator arm
NCT00370071 · Phase 3 · registry result, not featured evidence
show 1 more result
648 mm @ 24wk
NCT00370071 · Phase 3 · registry result, not featured evidence

+ 6 further endpoints in the CSV export.

peginterferon beta-1a

New or Enlarging T2 Lesion 7.9 vs 10.9 placebo lesions @ 52wkevery 4 weeks
event count · lesions
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
3.6 vs 10.9 placebo lesions @ 52wkevery 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Proportion Relapsed 0.222% (n=500) vs 0.291% (n=500) placebo @ 52wkevery 4 weeks
responder rate · % of participants
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.187% (n=512) vs 0.291% (n=500) placebo @ 52wkevery 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Sustained Disability Progression 0.068 vs 0.105 placebo ratio @ 52wkevery 4 weeks
event count · ratio
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.068 vs 0.105 placebo ratio @ 52wkevery 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Time to First Relapse NA vs 5.47 placebo months @ 96wk125 µg
time to event · months
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
New or Newly Enlarging T2 Lesion 1 vs 3.3 placebo count @ 48wk125 µg
event count · count
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
1.3 vs 3.5 placebo count @ 96wk125 µg
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Gd-enhancing Lesion 0 vs 1.5 placebo count @ 48wk125 µg
event count · count
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.25 vs 0.5 placebo count @ 96wk125 µg
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Relapse 29% (n=529)Q4W
responder rate · % of participants
No placebo or comparator arm
Relapsed
NCT01332019 · Phase 3 · monotherapy
show 1 more result
23% (n=547)Q2W
Relapsed
NCT01332019 · Phase 3 · monotherapy
New or Enlarging T2 Lesion 4.4 lesions @ 48wkQ4W
event count · lesions
No placebo or comparator arm
NCT01332019 · Phase 3 · monotherapy
show 3 more results
1.9 lesions @ 48wkQ2W
NCT01332019 · Phase 3 · monotherapy
8.9 lesions @ 96wkQ4W
NCT01332019 · Phase 3 · monotherapy
3.9 lesions @ 96wkQ2W
NCT01332019 · Phase 3 · monotherapy
New T1 Hypointense Lesion 1.4 lesions @ 49wkQ4W
event count · lesions
No placebo or comparator arm
NCT01332019 · Phase 3 · monotherapy
show 3 more results
0.8 lesions @ 49wkQ2W
NCT01332019 · Phase 3 · monotherapy
2.8 lesions @ 96wkQ4W
NCT01332019 · Phase 3 · monotherapy
1.5 lesions @ 96wkQ2W
NCT01332019 · Phase 3 · monotherapy
Gadolinium Enhancing Lesion 0.7 lesions @ 48wkQ4W
event count · lesions
No placebo or comparator arm
Week 48; n=481, 493
NCT01332019 · Phase 3 · monotherapy
show 1 more result
0.2 lesions @ 48wkQ2W
Week 48; n=481, 493
NCT01332019 · Phase 3 · monotherapy
Gadolinium Enhancing Lesion 0.8 lesions @ 96wkQ4W
event count · lesions
No placebo or comparator arm
Week 96; n=411, 407
NCT01332019 · Phase 3 · monotherapy
show 1 more result
0.2 lesions @ 96wkQ2W
Week 96; n=411, 407
NCT01332019 · Phase 3 · monotherapy
T2 Lesion Volume 11.7421 cm @ 48wkQ4W
absolute value · cm
No placebo or comparator arm
Week 48; n=481, 493
NCT01332019 · Phase 3 · monotherapy
show 1 more result
9.8335 cm @ 48wkQ2W
Week 48; n=481, 493
NCT01332019 · Phase 3 · monotherapy

+ 58 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Interferon beta-1b's landscape · peginterferon beta-1a's landscape